以上- For printing
- March 29, 2024
Eisai Co., Ltd. (Headquarters: Tokyo, Representative Executive Officer and CEO: Haruo Naito) is now offering a remedy for dizziness and balance disorders “Melislon”” (generic name: betahistine mesylate) and muscle tone improver “myonalI would like to inform you that we have signed an agreement to transfer domestic rights to” (generic name: eperisone hydrochloride) to Kenken Pharmaceutical Co., Ltd. (Headquarters: Tokyo, hereafter, Kenkaku Pharmaceutical).
“Melislon” and “Mionar” are drugs that have been used by many patients for a long time since their release in 1969 and 1983, respectively, in Japan. Now, in order for both drugs to continue contributing to more patients, it has been determined that the best choice is to transfer both drugs to Kankaku Pharmaceutical, which has strengths in the disease area. Based on this agreement, we will receive 3.8 billion yen as compensation, proceed with the transfer of sales functions around the end of March 2025, and then take over manufacturing and sales approvals. There is no change in our consolidated earnings forecast for the fiscal year ending 2024/3 due to this incident.
Based on the human health care philosophy, we position the “neurological domain,” “cancer area,” and “global health” as strategically important areas, and create innovative new drugs targeting diseases with high unmet medical needs,hhcAs an eco company, we aim to efficiently realize the social good of people's “resolution of health concerns” and “correction of medical care ranges” through the construction of an ecosystem through cooperation with other industries.
over
- 1. Scientific Research Pharmaceutical Co., Ltd.regarding
Scientific Research Pharmaceutical Co., Ltd. (hereafter, Scientific Research Pharmaceutical) is a pharmaceutical company established in 1948 with the corporate philosophy of “working to improve the quality of life of patients through the provision of excellent pharmaceuticals so that as many people as possible can return smiles.” As a research and development type pharmaceutical company, Kaken Pharmaceutical focuses on the dermatology and orthopedic fields, and continues to create and provide revolutionary new drugs in order to contribute to the “smiles” of suffering patients, their families, and medical personnel involved in treatment.
For details, seehttps://www.kaken.co.jp/Please take a look.
